文献速递淋巴瘤造血干细胞移植与细胞治疗

基于移植后环磷酰胺的单倍型相合移植作为霍奇金淋巴瘤同胞相合或无关供者移植的替代方案:欧洲血液与骨髓移植学会淋巴瘤工作组登记研究

Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
PubMed 文献 · J Clin Oncol · 2017-08-28

该登记研究回顾性评估709例接受异基因造血干细胞移植的成人霍奇金淋巴瘤患者,比较基于移植后环磷酰胺的单倍型相合(HAPLO,n=98)、同胞相合(SIB,n=338)和无关供者(MUD,n=273)移植的结局。中位随访29个月,HAPLO与SIB或MUD的总生存和无进展生存无显著差异,HAPLO慢性GVHD风险低于MUD,且广泛慢性GVHD无复发生存复合终点优于SIB。结论提示无常规供者时HAPLO可行。

要点

  • HAPLO与SIB或MUD的总生存和无进展生存无显著差异。
  • HAPLO慢性GVHD发生率26%,低于MUD的41%(P=0.04)。
  • 广泛慢性GVHD无复发生存复合终点HAPLO为40%,优于SIB的28%(P=0.049)。

核心结论

  • 基于移植后环磷酰胺的HAPLO移植与SIB和MUD相比生存结局相似,确认无常规供者时其适用性。
  • 结果还提示HAPLO慢性GVHD风险低于MUD移植。

研究设计与样本

  • 回顾性评估欧洲血液与骨髓移植学会数据库登记的709例成人霍奇金淋巴瘤患者,接受HAPLO(n=98)、SIB(n=338)或MUD(n=273)移植。
  • 存活者中位随访29个月。

主要发现

  • 各组急性GVHD发生率无差异。
  • HAPLO慢性GVHD发生率26%,MUD为41%(P=0.04)。
  • 1年非复发死亡率HAPLO 17%、SIB 13%、MUD 21%;2年复发或进展累积发生率HAPLO 39%、SIB 49%、MUD 32%。
  • 多因素分析:相对SIB,非复发死亡率HAPLO相似(P=0.26)、MUD更高(P=0.003);复发风险HAPLO(P=0.047)和MUD(P<0.001)均更低。
  • 2年总生存和无进展生存:HAPLO 67%和43%,SIB 71%和38%,MUD 62%和45%,HAPLO与SIB或MUD间无显著差异。

临床怎么用

  • 作者结论认为基于移植后环磷酰胺的HAPLO移植与SIB和MUD生存结局相似,确认无常规供者时其适用性。
  • 作者结果提示HAPLO慢性GVHD风险低于MUD移植。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose To compare the outcome of patients with Hodgkin lymphoma who received post-transplantation cyclophosphamide-based haploidentical (HAPLO) allogeneic hematopoietic cell transplantation with the outcome of patients who received conventional HLA-matched sibling donor (SIB) and HLA-matched unrelated donor (MUD). Patients and Methods We retrospectively evaluated 709 adult patients with Hodgkin lymphoma who were registered in the European Society for Blood and Marrow Transplantation database who received HAPLO (n = 98), SIB (n = 338), or MUD (n = 273) transplantation. Results Median follow-up of survivors was 29 months. No differences were observed between groups in the incidence of acute graft-versus-host disease (GVHD). HAPLO was associated with a lower risk of chronic GVHD (26%) compared with MUD (41%; P = .04). Cumulative incidence of nonrelapse mortality at 1 year was 17%, 13%, and 21% in HAPLO, SIB, and MUD, respectively, and corresponding 2-year cumulative incidence of relapse or progression was 39%, 49%, and 32%, respectively. On multivariable analysis, relative to SIB, nonrelapse mortality was similar in HAPLO ( P = .26) and higher in MUD ( P = .003), and risk of relapse was lower in both HAPLO ( P = .047) and MUD ( P < .001). Two-year overall survival and progression-free survival were 67% and 43% for HAPLO, 71% and 38% for SIB, and 62% and 45% for MUD, respectively. There were no significant differences in overall survival or progression-free survival between HAPLO and SIB or MUD. The rate of the composite end point of extensive chronic GVHD and relapse-free survival was significantly better for HAPLO (40%) compared with SIB (28%; P = .049) and similar to MUD (38%; P = .59). Conclusion Post-transplantation cyclophosphamide-based HAPLO transplantation results in similar survival outcomes compared with SIB and MUD, which confirms its suitability when no conventional donor is available. Our results also suggest that HAPLO results in a lower risk of chronic GVHD than MUD transplantation.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Martínez C, Gayoso J, Canals C, et al. Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation as Alternative to Matched Sibling or Unrelated Donor Transplantation for Hodgkin Lymphoma: A Registry Study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. J Clin Oncol. 2017. PMID: 28846465. doi:10.1200/JCO.2017.72.6869

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。